StreetInsider.com News Articles

TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint

Thu, 15 Oct 2026 03:05:00 -0400

Represents approximately US$500,000 in potential minimum purchases over the initial term and targets growing demand for medication temperature protection across insulin, GLP-1 therapies, biologics and other injectable medications

Toronto, Ontario--(Newsfile Corp. - October 15, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has executed a definitive exclusive distribution agreement dated September 14, 2026 (the "Distribution Agreement") with OGM For Import Medicine and Medical Supplies (the "Distributor" or "OGM") for the commercialization of TempraMed products in the State

TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint

Thu, 15 Oct 2026 03:05:00 -0400

TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint

Thu, 15 Oct 2026 03:05:00 -0400

TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint

Thu, 15 Oct 2026 03:05:00 -0400

TempraMed Granted Mexican Patent for Newest Product, VIVI Box

Thu, 08 Oct 2026 03:05:00 -0400

Grant in Mexico marks a major milestone in global IP strategy, advancing protection of its VIVI Box platform across key international markets

Highlights

Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform
Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets
Supports commercialization strategy and strategic engagement with appliance manufacturers across America's premium refrigeration sector
Patent term extends through October 24, 2039

Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased

TempraMed Granted Mexican Patent for Newest Product, VIVI Box

Thu, 08 Oct 2026 03:05:00 -0400

Grant in Mexico marks a major milestone in global IP strategy, advancing protection of its VIVI Box platform across key international markets

Highlights

Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform
Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets
Supports commercialization strategy and strategic engagement with appliance manufacturers across America's premium refrigeration sector
Patent term extends through October 24, 2039

TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking

Mon, 05 Oct 2026 03:05:00 -0400

VIVI Cap Smart transforms injectable medication protection into a connected health-data layer, enabling patients, caregivers and digital-health platforms to capture medication-use, temperature and adherence signals.

Toronto, Ontario--(Newsfile Corp. - October 5, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology company transforming the storage, protection and management of temperature-sensitive medications, is pleased to announce that its VIVI Cap Smart™ platform now supports connectivity with Apple Health and Google Fit, advancing the Company's strategy to make injectable medication use visible within leading health and wellness ecosystems.

VIVI Cap Smart™ is TempraMed's connected temperature-protection device

TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking

Mon, 05 Oct 2026 03:05:00 -0400

VIVI Cap Smart™ is TempraMed's connected temperature-protection device

TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking

Mon, 05 Oct 2026 03:05:00 -0400

VIVI Cap Smart™ is TempraMed's connected temperature-protection device

TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking

Mon, 05 Oct 2026 03:05:00 -0400

VIVI Cap Smart™ is TempraMed's connected temperature-protection device

TempraMed closes $1.18M private placement on CSE

Wed, 30 Sep 2026 18:02:09 -0400

TempraMed Technologies Ltd. (CSE: VIVI) has closed a non-brokered private placement, raising gross aggregate proceeds of $1,177,940 through the issuance of convertible debentures and units, according to a press release dated September 30, 2026.

The company issued $600,000 in principal amount of unsecured convertible debentures and 1,155,880 units. Each unit consists of one common share and one warrant, with each warrant exercisable to purchase one additional common share at C$1.00 on or before March 30, 2028.

The convertible debentures carry an interest rate of 10% per annum, calculated monthly and payable quarterly in cash. They mature on September 30, 2027, and may

TempraMed Technologies Ltd. Announces Closing of Private Placement

Wed, 30 Sep 2026 18:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), is pleased to announce that, further to its September 23, 2026 and September 28, 2026 news releases, it has closed its non-brokered private placement (the "Offering") of unsecured convertible debentures of the Company (each, a "Convertible Debenture") and units (each, a "Unit"). The Company issued $600,000 of principal amount of Convertible Debentures and 1,155,880 Units under the Offering for gross aggregate proceeds of $1,177,940.

Each Unit issued under the Offering consists of one common share in the capital of the Company (each, a

TempraMed Technologies Ltd. Announces Closing of Private Placement

Wed, 30 Sep 2026 18:00:00 -0400

Each Unit issued under the Offering consists of one common share in the capital of the Company (each, a

TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus

Tue, 29 Sep 2026 03:05:00 -0400

Distribution partnership with one of Cyprus's most established healthcare and consumer-products distributors

Highlights:

LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum combined unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Cyprus brings nearly a century of local market experience and established distribution capabilities spanning pharmaceutical products, medical instruments and hospital equipment.

Toronto, Ontario--(Newsfile Corp. - September

TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus

Tue, 29 Sep 2026 03:05:00 -0400

Distribution partnership with one of Cyprus's most established healthcare and consumer-products distributors

Highlights:

LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum combined unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Cyprus brings nearly a century of local market experience and established distribution capabilities spanning pharmaceutical products, medical instruments and hospital equipment.

Toronto, Ontario--(Newsfile Corp. - September

TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus

Tue, 29 Sep 2026 03:05:00 -0400

Distribution partnership with one of Cyprus's most established healthcare and consumer-products distributors

Highlights:

LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum combined unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Cyprus brings nearly a century of local market experience and established distribution capabilities spanning pharmaceutical products, medical instruments and hospital equipment.

Toronto, Ontario--(Newsfile Corp. - September

TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus

Tue, 29 Sep 2026 03:05:00 -0400

Distribution partnership with one of Cyprus's most established healthcare and consumer-products distributors

Highlights:

LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum combined unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Cyprus brings nearly a century of local market experience and established distribution capabilities spanning pharmaceutical products, medical instruments and hospital equipment.

Toronto, Ontario--(Newsfile Corp. - September

TempraMed Announces Upsize to Offering

Mon, 28 Sep 2026 17:49:00 -0400

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce an upsize (the "Upsized Offering") to the non-brokered private placement (the "Offering") previously announced on Wednesday, September 23, 2026. The Upsized Offering will include up to C$600,000 in unsecured convertible debentures (each, a "Debenture") and up to C$1,000,000 in units (each, a "Unit") for aggregate gross proceeds of up to C$1,600,000.

Each Unit will consist of one common share of the

TempraMed Announces Upsize to Offering

Mon, 28 Sep 2026 17:49:00 -0400

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

Each Unit will consist of one common share of the

TempraMed expands Latin American distribution and plans C$1M raise

Thu, 24 Sep 2026 02:57:15 -0400

TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) has amended its exclusive distribution agreement with TEM Consulting International S.A., extending the arrangement beyond Panama to Argentina, Venezuela, Colombia and Costa Rica, and adding the VIVI Med product to the covered portfolio.

The amended agreement also includes an additional commercial order from TEM, which TempraMed expects to fulfill by the end of September 2026. The initial extended-territory framework contemplates minimum unit commitments across the added countries, with additional annual commitments tied to exclusivity. TEM is responsible for obtaining all required governmental licenses, registrations, import authorizations and other regulatory approvals in each

TempraMed expands Latin American distribution and plans C$1M raise

Thu, 24 Sep 2026 02:57:15 -0400

TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement

Thu, 24 Sep 2026 02:55:00 -0400

Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations

Highlights

TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets.
The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™.
TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026.
Initial extended-territory framework contemplates minimum units across the added countries, with additional annual commitments tied to exclusivity.
Once required registrations are completed, TempraMed products are

TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement

Thu, 24 Sep 2026 02:55:00 -0400

Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations
Highlights
TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets.
The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™.
TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026.
Initial extended-territory framework contemplates minimum units across the added countries, with additional annual commitments tied to exclusivity.
Once required registrations are completed, TempraMed products are

TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement

Thu, 24 Sep 2026 02:55:00 -0400

Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations
Highlights
TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets.
The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™.
TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026.
Initial extended-territory framework contemplates minimum units across the added countries, with additional annual commitments tied to exclusivity.
Once required registrations are completed, TempraMed products are

TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement

Thu, 24 Sep 2026 02:55:00 -0400

Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations
Highlights
TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets.
The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™.
TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026.
Initial extended-territory framework contemplates minimum units across the added countries, with additional annual commitments tied to exclusivity.
Once required registrations are completed, TempraMed products are